EANS-Adhoc

Marinomed Biotech AG resumes offer period of the IPO

--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Stock Offerings (IPO)
23.01.2019

Vienna - 23 January 2019. Marinomed Biotech AG has decided to resume its initial
public offering and listing on the Vienna Stock Exchange (the "Offering"). The
Offer Period that was suspended on 29 November 2018 will be resumed on and
including Thursday 24 January 2019 and is expected to end on Tuesday 29 January
2019. The Offering comprises a public offering to retail and institutional
investors in Austria, a private placement outside Austria to selected
institutional investors, including a private placement within the United States
of America to qualified institutional buyers in reliance on Rule 144A under the
US Securities Act of 1933, as amended, and a private placement outside of the
United States of America to certain other eligible institutional investors in
reliance on Regulation S under the US Securities Act of 1933, as amended.

The Price Range for the offered shares of EUR 75 to 90 per share remains
unchanged. The final Offer Price is expected to be determined and announced on
29 January 2019. The expected settlement date and first trading day is 1
February 2019. From this date the Marinomed shares are intended to be traded
under the symbol "MARI" on the official market (prime market segment) of the
Vienna Stock Exchange.

The Offering size has been adapted and comprises up to 260,000 new bearer shares
(base size), which may be increased by up to 40,000 new bearer shares (the
upsize option). In addition, the Offering may be increased by up to a further
15% (up to 45,000 new bearer shares) on top of the base size and the upsize
option, if any, through exercise of an over-allotment option (greenshoe option).
The gross proceeds of the Offering based on the Price Range is thus supposed to
be between EUR 22.4m (at the lower end of the price range, without exercise of
the upsize option and including the exercise of the greenshoe option) and EUR
31.1m (at the upper end of the price range, including exercise of the upsize
option and greenshoe option).

The proceeds from the Offering shall be used primarily to fund the Pivotal Phase
III study of Budesolv, Phase II and Phase III studies of Tacrosolv as well as
the extension of the Carragelose OTC platform.